Cooperative Agreement U01CA294756
Award Date
9/1/24
Completion Date
8/31/29
Dollars Obligated
$1.8M
Federal Agency
National Cancer Institute
Federal Grant Program
93.393
Assistance Type
Cooperative Agreement
Place of Performance
New York, USA
Similar Awards
This $643,363 Cooperative Agreement, awarded by the National Cancer Institute (NCI) under the Cancer Cause and Prevention Research program (CFDA 93.393), will support a hybrid type III effectiveness-implementation trial to test best practices for deploying a "screen and treat" approach to cervical cancer screening using self-collected HPV DNA testing within HIV care and treatment facilities in Mozambique. The primary outcome is to increase the number of women screened and treated for...
This Cooperative Agreement award from the National Cancer Institute (NCI), under the federal grant program "Cancer Detection and Diagnosis Research" (CFDA 93.394), aims to develop a point-of-care HPV DNA test for cervical cancer screening in Mozambique. The total award is $585,943, with a performance period from September 1, 2024 to August 31, 2029. The key objectives are to: 1) Adapt existing extraction-free, multiplexed, isothermal nucleic acid amplification assays to detect 8...
This Cooperative Agreement award from the National Cancer Institute (NCI), under the Cancer Cause and Prevention Research (CFDA 93.393) program, aims to develop and evaluate an evidence-based, behavioral cervical cancer screening intervention for women living with HIV in Ghana. The $511,959 award to Baylor University will fund a hybrid effectiveness-implementation trial to integrate and scale up a home-based HPV self-sampling and communication model intervention called HOPE. The project seeks to...
The National Cancer Institute (NCI) awarded a 5-year, $629,068 Cooperative Agreement (CFDA 93.393 - Cancer Cause and Prevention Research) to Albert Einstein College of Medicine to conduct an implementation study of integrated human papillomavirus (HPV) self-sampling in HIV care centers in Ethiopia. The study aims to leverage the Project ECHO (Extension for Community Healthcare Outcomes) virtual learning platform to promote experience sharing and technical assistance across 5 hospitals to improve...
The Cooperative Agreement awarded by the National Cancer Institute (NCI) under the Cancer Cause and Prevention Research program (CFDA 93.393) provides $1,245,116 to Emory University from September 1, 2024 to August 31, 2029. The project, "Enhancing Cervical Cancer Screening and Treatment in Women Living with HIV in Kenya (ENHANCE Linkage)", aims to adapt and test implementation strategies to expand HIV care to screen for and treat early precancerous cervical cancer lesions in a...
This Cooperative Agreement award, funded by the National Cancer Institute (NCI) under the Cancer Biology Research program (CFDA 93.396), aims to develop and test novel vaccine platforms against Kaposi's Sarcoma-Associated Herpesvirus (KSHV) infection. The key objectives are: 1) to test three different KSHV vaccine platforms, and 2) to develop a chimeric murine herpesvirus 68 (MHV68) expressing KSHV glycoproteins as a surrogate challenge virus for evaluating KSHV vaccine efficacy in a mouse...
The National Cancer Institute (NCI) awarded a 5-year, $706,365 Cooperative Agreement (CFDA 93.393 - Cancer Cause and Prevention Research) to The Trustees of Columbia University in the City of New York to implement the WHO-endorsed "screen, triage, and treat" (ISTAR) approach for cervical cancer screening among women living with HIV in La Romana, Dominican Republic. The project aims to sustain implementation of the ISTAR approach and generate new data to inform effective and equitable...
This Project Grant award from the National Cancer Institute (CFDA 93.396 - Cancer Biology Research) provides $630,506 to The Johns Hopkins University to develop and test a therapeutic vaccine against cervical cancer associated with variants of the human papillomavirus type 16 (HPV16). The primary goals are to: 1) characterize how different HPV16 variants evade immune system detection, 2) study the growth and tumor microenvironment of spontaneous cervical/vaginal cancers driven by HPV16...
The National Cancer Institute (NCI) awarded a $233,411 Project Grant under the Cancer Cause and Prevention Research (CFDA 93.393) program to Pennsylvania State University's Milton S. Hershey Medical Center. The grant, titled "STORIES TO PREVENT (STOP) HPV CANCERS: A COMMUNICATION INTERVENTION TO INCREASE HPV VACCINATION AMONG DIVERSE POPULATIONS", aims to evaluate the impact of a narrative communication intervention delivered through digital and mobile technology on HPV vaccine...
The U.S. National Cancer Institute (NCI) awarded a $632,241 Cooperative Agreement (CFDA 93.393 - Cancer Cause and Prevention Research) to The Johns Hopkins University to leverage the existing HIV care infrastructure in Uganda to implement a comprehensive liver cancer control strategy, called the Liver Cancer Comprehensive Control (LC3) package. The LC3 package integrates the diagnosis and treatment of hepatitis B, primary prevention through adult vaccination, and referral for liver disease...